Spyre Therapeutics, Inc.
SYRE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$11,183 | -$36,717 | -$44,773 | -$56,296 |
| Dep. & Amort. | $0 | $0 | $0 | $0 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $9,378 | $8,859 | $9,216 |
| Change in WC | $5,940 | -$9,041 | -$568 | $10,798 |
| Other Non-Cash | -$31,874 | -$10,183 | -$4,512 | -$917 |
| Operating Cash Flow | -$37,117 | -$46,563 | -$40,994 | -$37,199 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | $0 | $0 | $0 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$74,193 | -$34,868 | -$71,444 | -$233,092 |
| Inv. Sales/Matur. | $99,191 | $106,866 | $71,383 | $62,548 |
| Other Inv. Act. | $0 | $7,000 | $0 | $0 |
| Investing Cash Flow | $24,998 | $78,998 | -$61 | -$170,544 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $491 | $731 | $0 | $224,622 |
| Stock Repurch. | $0 | $0 | -$117 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$5,134 | $0 | $242 | $979 |
| Financing Cash Flow | -$4,643 | $731 | $125 | $225,601 |
| Forex Effect | $0 | $0 | $0 | -$15 |
| Net Chg. in Cash | -$16,762 | $33,166 | -$40,930 | $17,843 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $81,659 | $48,493 | $89,423 | $71,580 |
| End Cash | $64,897 | $81,659 | $48,493 | $89,423 |
| Free Cash Flow | -$37,117 | -$46,563 | -$40,994 | -$37,199 |